期刊
BMJ CASE REPORTS
卷 14, 期 4, 页码 -出版社
BMJ PUBLISHING GROUP
DOI: 10.1136/bcr-2021-242956
关键词
healthcare improvement and patient safety; vaccination; immunisation; neurology; radiology; COVID-19
This case report highlights a rare occurrence of Guillain-Barre syndrome following COVID-19 vaccination. The patient received treatment with intravenous immunoglobulin and did not require respiratory support, and is currently on the path to recovery with multidisciplinary team follow-up.
Prevention strategies for COVID-19 transmission are at the forefront of healthcare paradigms worldwide, the main emphasis of which is vaccination. We present an interesting case of a 37-year-old man who, 3 weeks following his first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1, presented to hospital with a rapidly progressive ascending muscle weakness and back pain in the absence of any other triggers. He also had a negative COVID-19 swab during admission. A diagnosis of Guillain-Barre syndrome was confirmed by correlating the clinical features with cerebrospinal fluid analysis, nerve conduction studies and MRI of the brain and whole spine. The patient received treatment with 5 days of intravenous immunoglobulin and did not require any respiratory support. He was also regularly reviewed by a multidisciplinary team consisting of neurologists, speech and language therapists, and physiotherapists and is on the course to a recovery.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据